menu
    • menu

    Company profile for Oryzon Genomics

    NEW Drugs in Dev: 3
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oryzon GenomicsSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Sant Ferran 74 08940 Cornellà de Llobregat Barcelona
    Telephone
    Telephone
    (+34) 93 515 1313
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oryzon.com/en
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    ChemTides

    Not Confirmed

    envelop Contact Supplier

    ChemTides

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORYZON Secures Mexico Patent For Iadademstat Combo
    ORYZON Secures Mexico Patent For Iadademstat Combo

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254559/0/en/ORYZON-Expands-Patent-Protection-for-Iadademstat-with-Grant-Decision-in-Mexico-Covering-Combinations-with-PD-1-PD-L1-Inhibitors.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    ORYZON Reports Financial Results and Corporate Update
    ORYZON Reports Financial Results and Corporate Update

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246699/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-December-31st-2025.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    ORYZON To Participate In Upcoming Events In February & March
    ORYZON To Participate In Upcoming Events In February & March

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241044/0/en/ORYZON-to-Participate-in-Upcoming-Events-in-February-and-March.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Oryzon Appoints Rolando Gutierrez as Chief Medical Officer
    Oryzon Appoints Rolando Gutierrez as Chief Medical Officer

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237158/0/en/ORYZON-Announces-Appointment-of-Rolando-Gutierrez-Esteinou-M-D-as-Chief-Medical-Officer-for-CNS.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234486/0/en/ORYZON-Announces-First-Patient-Dosed-in-an-Investigator-Initiated-Phase-Ib-Study-of-Iadademstat-in-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    ORYZON Granted New Patent For Vafidemstat In Japan
    ORYZON Granted New Patent For Vafidemstat In Japan

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230223/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Vafidemstat-With-New-Decision-to-Grant-in-Japan.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search